Table 4.

Adverse drug reactions and discontinuation of adalimumab in patients with a history of anti-TNFα therapy.

	Discontinuation of previous anti-TNFα therapy due to ADRs			Discontinuation of previous anti-TNFα therapy due to reasons other than ADRs [n = 885]	p-Valuea
	Acute ADRs [n = 312]	Delayed ADRs [n = 109]	Total [n = 415]
Discontinuation of adalimumab therapy, n [%]
No	274 [87.8]	87 [79.8]	356 [85.8]	714 [80.7]	0.0245
Yes	38 [12.2]	22 [20.2]	59 [14.2]	171 [19.3]
Discontinuation of adalimumab therapy due to ADRs, n [%]
No	295 [94.6]	96 [88.1]	385 [92.8]	851 [96.2]	0.0085
Yes	17 [5.4]	13 [11.9]	30 [7.2]	34 [3.8]
Incidence of ADRs, n [%]
No	233 [74.7]	66 [60.6]	297 [71.6]	721 [81.5]	< 0.0001
Yes	79 [25.3]	43 [39.4]	118 [28.4]	164 [18.5]
Incidence of serious ADRs, n [%]
No	291 [93.3]	101 [92.7]	387 [93.3]	834 [94.2]	0.4886
Yes	21 [6.7]	8 [7.3]	28 [6.7]	51 [5.8]

ADR, adverse drug reaction; TNF, tumour necrosis factor.

^aChi-square test.